{"id":"W2269544826","doi":"10.1182/blood.v122.21.4175.4175","title":"An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; CancerCare Manitoba; Princess Margaret Cancer Centre","funders":"","keywords":"Ofatumumab; Medicine; Fludarabine; Chronic lymphocytic leukemia; Internal medicine; Phases of clinical research; Oncology; Interim analysis; Refractory (planetary science); Pharmacology; Clinical trial; Leukemia; Cyclophosphamide; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002970848,0.002159867,0.00325931,0.0006848655,0.0007493672,0.001441036,0.001010218,0.00170212,0.004275973],"category_scores_gemma":[0.001235825,0.001096004,0.002342199,0.0005139092,0.001641173,0.001688091,0.0005102613,0.004161736,0.001015002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001173282,"about_ca_system_score_gemma":0.0018664,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001236624,"about_ca_topic_score_gemma":0.00307081,"domain_scores_codex":[0.9991482,0.0003981789,0.00003860525,0.0001371973,0.0000731629,0.0002046109],"domain_scores_gemma":[0.9989777,0.0001788764,0.0001670194,0.0001122524,0.00006199149,0.0005022149],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8077994,0.1133862,0.004590346,0.000442174,0.001160153,0.0004017314,0.0003194424,0.001665363,0.02827858,0.0002229144,0.001805927,0.03992786],"study_design_scores_gemma":[0.4441322,0.5458772,0.005488693,0.00001671127,0.000317515,0.0001777434,0.00005497346,0.0006464685,0.001640495,0.0001280546,0.001491428,0.00002852587],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926178,0.001485475,0.0005224,0.0003607493,0.0001953379,0.002799579,0.0007720354,0.00007171969,0.001174911],"genre_scores_gemma":[0.986822,0.001456928,0.001754981,0.0007462201,0.0003087033,0.00388373,0.001858815,0.00002938281,0.003139225],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004275973,"threshold_uncertainty_score":0.01571149,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02195042890963005,"score_gpt":0.3083522339784295,"score_spread":0.2864018050687994,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}